Whats new

Whats new.

Baird - Efti in Combo With Keytruda Shows Encouraging 35% ORR in 1L HNSCC; Maintain OP, US$6 PT (Analyst: Joel L. Beatty, MD)

July 11th 2024

For a copy of this research report please contact your Baird advisor

Go back